Publications

Ordered by citation count. Invited commentaries and editorials are listed with the essays.

• Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Jabs DA, Rosenbaum JT, Nussenblatt RB; Standardization of Uveitis Nomenclature (SUN) Working Group. Am J Ophthalmol, 2005;140(3):509–16.
• The 2019 American College of Rheumatology / European League Against Rheumatism classification criteria for IgG4-related disease. Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, et al. Ann Rheum Dis, 2020;79(1):77–87.
• Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Am J Ophthalmol, 2000;130(4):492–513.
• American College of Rheumatology / Spondylitis Association of America / Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis. Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, Smith JA, et al. Arthritis Rheumatol, 2016;68(2):282–298.
• Endotoxin-induced uveitis in rats as a model for human disease. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Nature, 1980;286(5773):611–613.
• Expert panel recommendations for the use of anti–tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, et al. Ophthalmology, 2014;121(3):785–796.e3.
• Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Arthritis Care Res, 2001;45(3):252–257.
• Epidemiology and course of disease in childhood uveitis. Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, et al. Ophthalmology, 2009;116(8):1544–1551.e1.
• Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Qu Z, Liebler JM, Powers MR, Galey T, Ahmadi P, Huang XN, Ansel JC, et al. Am J Pathol, 1995;147(3):564.
• Methotrexate for ocular inflammatory diseases. Gangaputra S, Newcomb CW, Liesegang TL, Kaçmaz RO, Jabs DA, et al. Ophthalmology, 2009;116(11):2188–2198.e1.
• Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Lim LL, Fraunfelder FW, Rosenbaum JT. Arthritis Rheum, 2007;56(10):3248–52.
• A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, et al. Arch Ophthalmol, 2005;123(7):903–912.
• Mycobacterial diseases and antitumour necrosis factor therapy in USA. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, et al. Ann Rheum Dis, 2013;72(1):37–42.
• HLA-B27 and human β2-microglobulin affect the gut microbiota of transgenic rats. Lin P, Bach M, Asquith M, Lee AY, Akileswaran L, Stauffer P, Davin S, et al. PLoS One, 2014;9(8):e105684.
• Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) initiative. Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R Jr, Brézin AP, Chee SP, et al. Ophthalmology, 2018;125(5):757–773.
• Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Smith JR, Rosenbaum JT, Wilson DJ, Doolittle ND, Siegal T, Neuwelt EA, et al. Ophthalmology, 2002;109(9):1709–1716.